Expected total fourth quarter revenue of $472-475M, including Screening revenue of $277-278M, Precision Oncology revenue of $148.5-149.5M, and COVID-19 testing revenue of $46.5-47.5M
- Total 2021 revenue, excluding COVID-19 testing, increased 29% compared to 2020, including 30% increase in Screening revenue and 27% increase in Precision Oncology revenue
- Screening revenue growth driven by Cologuard rescreens, Cologuard use in 45-49 age group, expansion of primary care sales team, and increased in-person sales calls
https://finance.yahoo.com/news/exact-sciences-announces-preliminary-fourth-000000623.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.